An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors

Karageorgis, Anastassia; Dufort, Sandrine; Sancey, Lucie; Henry, Maxime; Hirsjärvi, Samuli; Passirani, Catherine; Benoit, Jean‐Pierre; Gravier, Julien; Texier, Isabelle; Montigon, Olivier; Benmerad, Mériem; Siroux, Valérie; Barbier, Emmanuel; Coll, Jean‐Luc

doi:10.1038/srep21417

Cited by 54 publications

(47 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an alternative to companion nanodiagnostics and nanotheranostics, clinically established (but intuitively significantly less specific) 'standard' imaging protocols could be considered to predict the accumulation and efficacy of passively targeted cancer nanomedicines, such as dynamic contrast-enhanced MRI 39 , CT 40 and ultrasound 41 . Furthermore, future analyses should set out to evaluate if histopathological assessment of tumour biopsies can help to stratify responders from non-responders.…”

Section: Imaging Biomarkersmentioning

confidence: 99%

Smart cancer nanomedicine

et al. 2019

View full text Add to dashboard Cite

Nanomedicines are extensively employed in cancer therapy. We here propose four strategic directions to improve nanomedicine performance and translation. (1) Patient stratification has become common practice in oncology drug development. Accordingly, probes and protocols for patient stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclusion in clinical trials. (2) Rational drug selection is crucial for clinical and commercial success. Opportunistic choices based on drug availability should be replaced by investments in modular (pro)drug and nanocarrier design. (3) Combination therapies are the mainstay of clinical cancer care. Nanomedicines synergize with pharmacological and physical co-treatments, and should be increasingly integrated in multimodal combination therapy regimens. (4) Immunotherapy is revolutionising the treatment of cancer. Nanomedicines can regulate the behaviour of myeloid and lymphoid cells, thereby empowering anticancer immunity and immunotherapy efficacy. Alone and especially together, these four directions will fuel and foster the development of successful cancer nanomedicine therapies.

show abstract

Section: Imaging Biomarkersmentioning

confidence: 99%

Smart cancer nanomedicine

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Similarly, the cellular distribution in a mouse mammalian carcinoma was studied by nanotomography. This tumor type from mice origin is often selected for its huge capacity to accumulate any drugs after intravenous administration, since it has been reported to have an enhanced permeability and retention effect [ 49 ]. Figure 5(a) and 5(b) display two minimum intensity projection images selected from the nanotomography dataset.…”

Section: Resultsmentioning

confidence: 99%

X-ray Zernike phase contrast tomography: 3D ROI visualization of mm-sized mice organ tissues down to sub-cellular components

Longo¹,

Sancey²,

Flenner³

et al. 2020

Biomed. Opt. Express

View full text Add to dashboard Cite

Thanks to its non-invasive nature, X-ray phase contrast tomography is a very versatile imaging tool for biomedical studies. In contrast, histology is a well-established method, though having its limitations: it requires extensive sample preparation and it is quite time consuming. Therefore, the development of nano-imaging techniques for studying anatomic details at the cellular level is gaining more and more importance. In this article, full field transmission X-ray nanotomography is used in combination with Zernike phase contrast to image millimeter sized unstained tissue samples at high spatial resolution. The regions of interest (ROI) scans of different tissues were obtained from mouse kidney, spleen and mammalian carcinoma. Thanks to the relatively large field of view and effective pixel sizes down to 36 nm, this 3D approach enabled the visualization of the specific morphology of each tissue type without staining or complex sample preparation. As a proof of concept technique, we show that the high-quality images even permitted the 3D segmentation of multiple structures down to a sub-cellular level. Using stitching techniques, volumes larger than the field of view are accessible. This method can lead to a deeper understanding of the organs’ nano-anatomy, filling the resolution gap between histology and transmission electron microscopy.

show abstract

“…The functionalized nano-carriers, which are multidisciplinary products, including medicine, pharmacy, material science and engineering, have been an optimal choice to realize the combination therapy due to their a number of advantages, such as the passive targeting capacity by the enhanced permeation and retention (EPR), the large surface to volume ratio, the ability to load diverse drugs and the tunable surface for targeting modification [ 6 , 7 , 8 , 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Nanotechnology for Cancer Therapy Based on Chemotherapy

et al. 2018

View full text Add to dashboard Cite

Chemotherapy has been widely applied in clinics. However, the therapeutic potential of chemotherapy against cancer is seriously dissatisfactory due to the nonspecific drug distribution, multidrug resistance (MDR) and the heterogeneity of cancer. Therefore, combinational therapy based on chemotherapy mediated by nanotechnology, has been the trend in clinical research at present, which can result in a remarkably increased therapeutic efficiency with few side effects to normal tissues. Moreover, to achieve the accurate pre-diagnosis and real-time monitoring for tumor, the research of nano-theranostics, which integrates diagnosis with treatment process, is a promising field in cancer treatment. In this review, the recent studies on combinational therapy based on chemotherapy will be systematically discussed. Furthermore, as a current trend in cancer treatment, advance in theranostic nanoparticles based on chemotherapy will be exemplified briefly. Finally, the present challenges and improvement tips will be presented in combination therapy and nano-theranostics.

show abstract

An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors

Cited by 54 publications

References 41 publications

Smart cancer nanomedicine

Smart cancer nanomedicine

X-ray Zernike phase contrast tomography: 3D ROI visualization of mm-sized mice organ tissues down to sub-cellular components

Nanotechnology for Cancer Therapy Based on Chemotherapy

Contact Info

Product

Resources

About